In March 2021, Diaceutics offered labs a collaboration opportunity via DXRX – The Diagnostic Network®. The collaboration was an open call for FFPE tissue blocks to help Canadian Pathology Quality Assurance (CPQA-AQCP) build a small tissue microarray for the purpose of NTRK IHC proficiency testing as well as providing NTRK IHC validation assistance.
The focus of the collaboration with labs was to curate secretory breast carcinoma and/or salivary MASC blocks due to the higher incidence of NTRK Fusions in these tumours. Participating labs benefited from working with a renowned global EQA/ PT provider to support NTRK IHC proficiency testing and were eligible for free participation in the CPQA pan-TRK EQA program if the lab already offered an NTRK IHC service. The labs also received access to TMA slides and assistance for labs who wished to develop and validate Pan-TRK IHC.
Click here to read about Dr. Markus Eckstein's (MD. Institute of Pathology, University Hospital Erlangen, Germany) experience as a lab working on the DXRX Collaboration – NTRK IHC proficiency testing. https://www.diaceutics.com/uploads/dr-markus-eckstein-shares-a-lab-perspective-on-the-impacts-of-a-dxrx-collaboration-ntrk-ihc-proficiency-testing
To learn more about how a DXRX collaboration can help your lab solve real-world testing challenges ensuring every patient gets the treatment they deserve, click here: DXRX For Labs - Diaceutics
